NCPE — First National HTA Using EU Joint Clinical Assessment Data

The NCPE completed a rapid review of onasemnogene abeparvovec intrathecal (Itvisma®), Novartis’s intrathecal gene therapy for spinal muscular atrophy (SMA), making this the first national HTA assessment completed for a medicine undergoing an EU Joint Clinical Assessment (JCA) under the EU HTA Regulation. The JCA report was endorsed by the Member State Coordination Group on […]

UK–US Arrangement – Jersey & Guernsey

The UK–US Trade Agreement and the NICE threshold changes do not apply in Jersey or Guernsey, which are not part of the NHS and operate their own prescribing frameworks. While the arrangement does not bind either island, both Jersey and Guernsey procure most medicines through NHS supply chains or NHS framework agreements, meaning any increase […]